pdl biopharma inc
(PDLI:Consolidated Issue Listed on NASDAQ Global Select )
pdl biopharma inc (PDLI) Snapshot
|
Open
$7.73
|
Previous Close
$7.74
|
|
|
Day High
$7.94
|
Day Low
$7.70
|
|
|
52 Week High
05/22/13 - $8.48
|
52 Week Low
06/19/12 - $6.32
|
|
|
Market Cap
1.1B
|
Average Volume 10 Days
1.8M
|
|
|
EPS TTM
$1.54
|
Shares Outstanding
140.0M
|
|
|
EX-Date
09/3/13
|
P/E TM
5.1x
|
|
|
Dividend
$0.60
|
Dividend Yield
7.58%
|
Related News
pdl biopharma inc (PDLI) Related Businessweek News
No Related Businessweek News Foundpdl biopharma inc (PDLI) Details
PDL BioPharma, Inc. engages in intellectual property asset management and patent portfolio and related assets investment activities. The company is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases, as well as other medical conditions. It offers Queen et al. patents that cover humanized antibodies, methods for humanizing antibodies, polynucleotide encoding in humanized antibodies, and methods of producing humanized antibodies. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.
pdl biopharma inc (PDLI) Top Compensated Officers
pdl biopharma inc (PDLI) Key Developments
PDL BioPharma, Inc. provided royalty revenue guidance for the second quarter ending June 30, 2013. For the quarter, the company expects royalty revenue of approximately $143 million, as compared with actual royalty revenue of $126 million for the second quarter of 2012, an approximate 14% increase.
PDL BioPharma, Inc. Presents at Goldman Sachs 34th Annual Global Healthcare Conference, Jun-11-2013 10:40 AM. Venue: Terranea Resort, Rancho Palos Verdes, California, United States. Speakers: John P. McLaughlin, Chief Executive Officer, President, Director and Member of Litigation Committee.
PDL BioPharma, Inc. amended the restated certificate of incorporation of the company to increase the authorized common share capital of the company from 250,000,000 to 350,000,000 shares.
| Recently Viewed | |||
| PDLI:US | $7.92 USD | +0.18 |  |
| Company | Last | Change | |
| No competitor information is available for PDLI. | |||
| View Industry Companies | |||
Industry Analysis
PDLI
Industry Average
| Valuation | PDLI | Industry Range |
| Price/Earnings | 5.1x |
|
| Price/Sales | 2.8x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | 4.8x |
|
| TEV/Sales | 1.5x |
|
Post a JobJobs
- Chicago, IL | DunnhumbyusaPosted: Jun 18
- Thomasville, GA | Flowers FoodsPosted: Jun 07
- San Francisco, CA | YelpPosted: Jun 06
- San Francisco, CA | PeoplematterPosted: Jun 06
Sponsored Financial Commentaries
Sponsored Links
To contact PDL BIOPHARMA INC, please visit www.pdl.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
